SecuritySPPI / Spectrum Pharmaceuticals, Inc. (84763A108)
IndustryPharmaceutical Preparations
Common Shares Outstanding102,714,556 shares (as of 2017-12-31)
Total Insiders12
Total Directors9
Total Officers4

Stock Insider Trading (from SEC Form 4)

SPPI / Spectrum Pharmaceuticals, Inc. Insider Trades

Spectrum Pharmaceuticals, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

SPPI / Spectrum Pharmaceuticals, Inc. insiders include GUSTAFSON KURT A, ALLEN LEE F MD PhD, Riga Thomas J, LENAZ LUIGI MD, COHEN RAYMOND W, Turgeon Joseph W., Vyas Dolatrai, MAIDA ANTHONY E III, Ashton William Krassner Stuart Mitchell, Gagnon Gilles, and SHROTRIYA RAJESH C MD, .

Insider Roster

Insider Dir Off 10% Shares Owned
LENAZ LUIGI MD Director
X 109,077
Krassner Stuart Mitchell Director
X 57,944
SHROTRIYA RAJESH C MD Director
X 4,155,289
COHEN RAYMOND W Director
X 28,850
Riga Thomas J EVP, COO & CCO
X 247,555
Turgeon Joseph W. CEO & President, Director
X X 316,509
GUSTAFSON KURT A EVP & Chief Financial Officer
X 193,739
Ashton William Director
X 0
MAIDA ANTHONY E III Director
X 31,505
Vyas Dolatrai Director
X 37,079
Gagnon Gilles Director
X 82,500
ALLEN LEE F MD PhD Chief Medical Officer
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-22 4 LENAZ LUIGI MD M D 1.47 40,000 109,077
2018-05-17 4 Krassner Stuart Mitchell S D 18.94 -21,113 57,944 1,097,459
2018-05-17 4 SHROTRIYA RAJESH C MD By CS Family Trust G I 362,926 4,155,289
2018-05-17 4 SHROTRIYA RAJESH C MD G D -362,926 3,377,052
2018-05-17 4 SHROTRIYA RAJESH C MD M D 1.47 250,426 3,739,978
2018-05-17 4 SHROTRIYA RAJESH C MD M D 1.43 112,500 3,489,552
2018-05-14 4 COHEN RAYMOND W S D 18.32 -9,275 28,850 528,532
2018-05-14 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.38 -24,014 3,953,015 72,656,416
2018-05-11 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.55 -30,000 3,977,029 69,796,859
2018-05-10 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.13 -30,000 4,007,029 68,640,407
2018-05-14 4 Riga Thomas J S X D 18.101 -3,290 247,555 4,480,993
2018-05-09 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.21 -30,000 4,037,029 65,440,240
2018-05-08 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.11 -30,000 4,067,029 65,519,837
2018-05-07 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.98 -30,000 4,097,029 65,470,523
2018-05-04 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.79 -30,000 4,127,029 69,292,817
2018-05-03 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.01 -30,000 4,157,029 66,554,034
2018-05-02 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.04 -30,000 4,187,029 67,159,945
2018-05-01 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.77 -30,000 4,217,029 66,502,547
2018-04-30 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.36 -30,000 4,247,029 69,481,394
2018-04-27 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.17 -30,000 4,277,029 73,436,588
2018-04-26 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.26 -30,000 4,307,029 74,339,321
2018-04-25 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.26 -30,000 4,337,029 74,857,121
2018-04-24 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.11 -30,000 4,367,029 79,086,895
2018-04-23 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.37 -30,000 4,397,029 80,773,423
2018-04-20 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.67 -30,000 4,427,029 82,652,631
2018-04-19 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 19.18 -30,000 4,457,029 85,485,816
2018-04-18 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 19.71 -30,000 4,487,029 88,439,342
2018-04-17 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.56 -30,000 4,517,029 83,836,058
2018-04-16 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 18.72 -30,000 4,547,029 85,120,383
2018-04-17 4 Turgeon Joseph W. S X D 19.0014 -11,565 316,509 6,014,114
2018-04-17 4 Riga Thomas J S X D 19.0667 -1,840 250,778 4,781,509
2018-04-16 4 Riga Thomas J S X D 18.595 -3,900 261,618 4,864,787
2018-04-13 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 19.93 -30,000 4,577,029 91,220,188
2018-04-12 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 20.72 -30,000 4,607,029 95,457,641
2018-04-11 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 20.30 -30,000 4,637,029 94,131,689
2018-04-10 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.74 -30,000 4,667,029 82,793,094
2018-04-09 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.01 -12,300 4,697,029 70,502,405
2018-04-06 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.00 -3,686 4,709,329 70,639,935
2018-04-05 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.33 -30,000 4,713,015 72,250,520
2018-04-04 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.01 -30,000 4,743,015 71,192,655
2018-04-03 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.14 -30,000 4,773,015 72,263,447
2018-04-02 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 15.61 -30,000 4,803,015 74,975,064
2018-03-29 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.18 -30,000 4,833,015 78,198,183
2018-04-02 4 Riga Thomas J S X D 15.58 -1,948 263,376 4,103,398
2018-03-28 4 GUSTAFSON KURT A S X D 16.35 -4,350 193,739 3,167,633
2018-03-28 4 Turgeon Joseph W. S X D 16.40 -4,810 328,074 5,380,414
2018-03-28 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 16.19 -30,000 4,863,015 78,732,213
2018-03-27 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.10 -30,000 4,893,015 83,670,556
2018-03-26 4 SHROTRIYA RAJESH C MD By CS Family Trust S X I 17.34 -30,000 4,923,015 85,365,080
2018-03-26 4 Riga Thomas J S X D 17.41 -220 258,400 4,498,744
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

OncoMed Pharmaceuticals: Assessing The Prospect Of A Potential Robust Winner

2018-05-21 seekingalpha
As a promising grower, OncoMed is leveraging on the “more shots on goal” strategy. Despite earlier missed clinical outcomes, the company is brewing stellar molecules that are approaching their binaries. (100-0)

Your Daily Pharma Scoop: RARE Shows Solid Data, Spectrum Up On Positive Results, Syndax Entinostat Performs Poorly

2018-05-18 seekingalpha
Ultragenyx (NASDAQ:RARE), which we recommended as a buy in October 2017 when it was trading at 52-week lows, has been up 50% since our recommendation. We recommended it on the basis of an upcoming approval of its Sly syndrome treatment MEPSEVII in November - which happened; and another approval of borosumab (Crysvita) in April - which also happened. We also liked its cash position, both then and now, and its sale of a Rare Disease Priority Review voucher for $130mn. (129-0)

Rounds Report: Eiger Moved Northbound While Spectrum Rallied Strongly Due To ADVANCE Trial Results

2018-05-18 seekingalpha
The overall bioscience market racked up significant gains. Many companies under our coverage moved further north. (15-0)

Ligand (LGND) Beats on Q1 Earnings & Revenues, Keeps View

2018-05-09 zacks
Ligand Pharmaceuticals Incorporated (LGND - Free Report) reported first-quarter 2018 adjusted earnings of $1.55 per share, significantly up from the year-ago figure of 57 cents. The bottom line also beat the Zacks Consensus Estimate of $1.28. (97-1)

Spectrum (SPPI) Earnings and Sales Beat Estimates in Q1

2018-05-04 zacks
Spectrum Pharmaceuticals, Inc. (SPPI - Free Report) incurred a loss of 16 cents per share in the first quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of 24 cents and the year-ago quarter loss of 30 cents per share. However, adjusted loss came in at 15 cents, wider-than the year ago loss of 14 cents. (89-1)